Surgical management of Graves' disease: Preoperative preparation and extent of surgery

Problems in General Surgery

Volumn 14, Issue 4, 1997, Pages 132-154

  Rastad, Jonas ^a   Karlsson, F Anders ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; GLUCOCORTICOID; IODIDE; IODINE; PROPYLTHIOURACIL; THIAMAZOLE; THIONAMIDE DERIVATIVE; THIOURACIL; THYROID PEROXIDASE; THYROTROPIN; THYROTROPIN RECEPTOR; THYROTROPIN RECEPTOR ANTIBODY;

CLINICAL FEATURE; EYE DISEASE; GRAVES DISEASE; HUMAN; HYPOTHYROIDISM; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SURGICAL TECHNIQUE; THYROIDECTOMY; THYROTOXICOSIS; TREATMENT OUTCOME;

EID: 0031470591     PISSN: 07398328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (145)

1. Solomon B, Glinoer D, Lagasse R, Wartofsky L. Current trends in the management of Graves' disease. J Clin Endocrinol Metab 1990;70:1518-24.
2. Ross DS. The medical management of Graves' disease. Endocr Pract 1995;1:193-6.
3. Levetan C, Wartofsky L. A clinical guide to the management of Graves' disease with radioactive iodine. Endocr Pract 1995;1:205-12.
4. Marcocci C, Bartalena L, Bogazzi F, Bruno-Bossio G, Pinchera A. Relationship between Graves' ophthalmopathy and type of treatment of Graves' hyperthyroidism. Thyroid 1992;2:171-8.
5. Adlerbert A, Stenström G, Hasselgren P. The selective β1-blocking agent metoprolol compared with antithyroid drug and thyroxine as preoperative treatment of patients with hyperthyroidism. Ann Surg 1987; 205:182-8.
6. Allannic H, Fauchet R, Orgiazzi J, et al. Antithyroid drugs and Graves' disease: A prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab 1990;70:675-9.
7. Tallstedt L, Lundell G, Törring O, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. N Engl J Med 1992;326:1733-8.
8. Andåker L, Johansson K, Smeds S, Lennquist S. Surgery for hyperthyroidism: Hemithyroidectomy plus contralateral resection or bilateral resection? A prospective randomized study of postoperative complications and long-term results. World J Surg 1992;16:765-9.
9. Leading article. Treatment of hyperthyroidism. Lancet 1973;ii:82.
10. Petersen IA, Kriss JP, McDougall IR, et al. Prognostic factors in the radiotherapy of Graves' ophthalmopathy. Int J Radiat Oncol Biol Phys 1990;19:259-64.
11. Volpe R. The pathophysiology of autoimmune thyroid disease. Endocr Reg 1991;25:187-92.
12. Gerstein H, Rastogi B, Iwatani Y, Iitaka M, Row VV, Volpe R. The decrease in nonspecific suppressor T lymphocytes in female hyperthyroid Graves' disease is secondary to the hyperthyroidism. Clin Invest Med 1987; 10: 337-44.
13. Volpe R, Karlsson A, Jansson R, Dahlberg PA. Evidence that antithyroid drugs induce remission in Graves' disease by modulating thyroid cellular activity. Clin Endocrinol 1986;25:453-62.
14. Aguayo J, Iitaka M, Row VV, Volpe R. Studies of HLA-DR expression on cultered human thyrocytes: Effect of antithyroid drugs and other antigens on interferon gamma induced HLA-DR expression. J Clin Endocrinol Metab 1988;66:903-10.
15. Tötterman TH, Karlsson FA, Bengtsson M, Mendel-Hartvig I. Induction of circulating activated suppressor-like T cells by methimazole therapy for Graves' disease. N Engl J Med 1987;316:15-22.
16. Tomer Y, Davies TF. Infection, thyroid disease, and autoimmunity. Endocr Rev 1993;14:107-20.
17. Burman KD, Baker JR. Immune mechanisms in Graves' disease. Endocr Rev 1985;6:183-232.
18. Schleusener H, Peters H, Bogner U, et al. Immunogenetics in Graves' disease. An overview. Acta Endocrinol 1989:122(suppl 2):123-9.
19. Winsa B, Dahlberg PA, Jansson R, Ågren H, Karlsson FA. Factors influencing the outcome of thyrostatic drug therapy in Graves' disease. Acta Endocrinol 1990;122: 722-8.
20. Winsa B, Adami HO, Bergström R, et al. Stressful life events in Graves' disease. Lancet 1991;338:1475-9.
21. Smith BR, Hall R. Binding of thyroid stimulators to thyroid membranes. FEBS Lett 1974;42:301-4.
22. Creagh F, Teece M, Williams S, Didcote S, Perkins W, Hashim F, Rees Smith B. An analysis of thyrotrophin receptor binding and thyroid stimulating activities in a series of Graves' sera. Clin Endocrinol 1985;23: 395-404.
23. Hensen J, Kotulla P, Finke R, Bogner U, Badenhoop K, Meinhold H, Schleusener H. Methodological aspects and clinical results of an assay for thyroid-stimulating antibodies: correlation with thyrotrophin binding-inhibiting antibodies. J Endocrinol Metab 1984;58: 980-7.
24. Todd I, Pujol-Borrel R, Hammond LJ, Mc Nally JM, Feldmann M, Bottazzo GF. Enhancement of thyrocyte HLA class II expression by thyroid-stimulating hormone. Clin Exp Immunol 1987;69:524-31.
25. Gamstedt A, Karlsson FA. Pretreatment with betamethasone of patients with Graves' disease given radioiodine therapy: Thyroid autoantibody responses and outcome of therapy. J Clin Endocrinol Metab 1991; 73:125-31.
26. Westermark K, Nilsson M, Karlsson FA. Effects of interleukin 1 on porcine thyroid cells in suspension cultures. Acta Endocrinol 1990;122:505-12.
27. Davies Jones E, Hashim FA, Creagh FM, Williams SE, Rees Smith B. The interaction between the TSH receptor and Graves' sera with TSH agonist or antagonist properties. Mol Cell Endocrinol 1985;41:257-61.
28. Tamai H, Hirota Y, Kasagi K, et al. The mechanism of spontaneous hypothyroidism in patients with Graves' disease after antithyroid drug treatment. J Clin Endocrinol Metab 1987;64:718-22.
29. Mori Y, Matoba N, Miura S, Sakai N, Taira Y. Clinical course and thyroid stimulating hormone (TSH) receptor antibodies during surgical treatment of Graves' disease. World J Surg 1992;16:647-53.
30. Macchia E, Femzi GF, Monzani F. Comparison between thyroid stimulating and TSH-binding inhibiting immunoglobulins of Graves' disease. Clin Endocrinol 1981;15:175-82.
31. Murray D. The thyroid gland. In: Kovacs K, Asa SL, eds. Functional endocrine pathology. Oxford: Blackwell Scientific Publ, 1991:293-374.
32. McLachlan SM, Pegg CAS, Atherton MC, et al. TSH receptor antibody synthesis by thyroid lymphocytes. Clin Endocrinol 1986;24:223-30.
33. Atherton MC, McLachlan SM, Pegg CAS, et al. Thyroid autoantibody synthesis by lymphocytes from different lymphoid organs: Fractionation of B cells on density gradients. Immunology 1985;55:271-9.
34. Winsa B, Rastad J, Larsson E, et al. Total thyroidectomy in therapy-resistant Graves' disease. Surgery 1994;116:1068-75.
35. Winsa B, Rastad J, Åkerström G, Johansson H, Westermark K, Karlsson FA. Retrospective evaluation of subtotal and total thyroidectomy in Graves' disease with and without endocrine ophthalmopathy. Eur J Endocrinol 1995;132:406-12.
36. Furmaniak J, Bradbury J, Rees Smith B. Antibodies to membrane antigens in autoimmune thyroid disease. Acta Endocrinol 1987;116:13-20.
37. John R, Henley R, Shankland D. Concentrations of free thyroxin and free triiodothyronine in serum of patients with thyroxin- and triiodothyronine-binding autoantibodies. Clin Chem 1990;36:470-3.
38. Khoury EL, Bottatzzo GF, Roitt IM. The thyroid "microsomal" antibody revisited: Its paradoxical binding in vivo to the apical surface of the follicular epithelium. J Exp Med 1984;159:577-91.
39. Nakajima Y, Howells RD, Pegg C, Davies Jones E, Rees Smith B. Structure-activity analysis of microsomal antigen/thyroid peroxidase. Mol Cell Endocrinol 1987; 53:15-23.
40. Salvi M, Fukazawa H, Bernard N, Hiromatsu Y, How J, Wall JR. Role of autoantibodies in the pathogenesis and association of endocrine autoimmune disorders. Endocr Rev 1988;9:450-66.
41. Baker JR, Saunders NB, Wartofsky L, Tseng YL, Burman KD. Seronegative Hashimoto thyroiditis with thyroid autoantibody production localized to the thyroid. Ann Inten Med 1988;108:26-30.
42. Damante G, Charzenbalk G, Russo D, Rapoport B, Foti D, Filetti S. Thyrotropin regulation of thyroid peroxidase messenger ribonucleic acid levels in cultured rat thyroid: Evidence for the involvement of a nontranscriptional mechanism. Endocrinology 1989;124: 2889-94.
43. Bahn RS, Garrity JA, Gorman CA. Diagnosis an management of Graves' ophthalmopathy. J Clin Endocrinol Metab 1990;71:559-63.
44. Salvi M, Zang ZG, Haegert D, et al. Patients with endocrine ophthalmopathy not associated with overt thyroid disease have multiple thyroid immunological abnormalities. J Clin Endocrinol Metab 1990;70: 89-94.
45. Smith TJ, Bahn RS, Gorman CA. Connective tissue, glycosaminoglycans and diseases of the thyroid. Endocr Rev 1989;10:366-91.
46. Paschke R, Vassart G, Ludgate M. Current evidence for and against the TSH receptor being the common antigen in Graves' disease and thyroid associated immunology. Clin Endocrinol 1995;42:565-9.
47. Jaume JC, Prummel MF, Wiersinga WM, McLachlan SM, Rapoport B. Thyrotropin receptor autoantibodies recognizing two different epitopes on the TSH receptor: Lack of relationship to patient age, sex and ophthalmopathy. Thyroid 1993;3:291-5.
48. Burch HB, Sellitti D, Barnes SG, Nagy EV, Bahn RS, Burman KD. Thyrotropin receptor antisera for the detection of immunoreactive protein species in retroocular fibroblasts obtained from patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 1994;78: 1384-91.
49. Salvi M, Miller A, Wall JR. Human orbital tissue and thyroid membranes express a 64 kDa protein which is recognized by autoantibodies in the serum of patients with thyroid-associated ophthalmopathy. FEBS Lett 1988;232:135-9.
50. Bech K. Thyroid autoantibodies in endocrine ophthalmopathy. A review. Acta Endocrinol 1989;121 (suppl 2):117-22.
51. Karlsson FA, Dahlberg PA, Jansson R, Westermark K, Enoksson P. Importance of TSH receptor activation in the development of severe endocrine ophthalmopathy. Acta Endocrinol 1989;121(suppl 2):132-41.
52. Hancock SL, Cox RS, McDougali IR. Thyroid disease after treatment of Hodgkin's disease. N Engl J Med 1991;325:599-605.
53. Vestergaard H, Laurberg P. Radioiodine and aggravation of Graves' opthalmopathy. Lancet 1989;2:47.
54. Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 1989;321:1349-62.
55. Tallstedt L, Lundell G, Blomgren H, Bring J. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment. Eur J Endocrinol 1994;130:494-7.
56. Dillman WH. The cardiovascular system in thyrotoxicosis. In: Braverman LE, Utiger RD, eds. Werner and Ingbar's The Thyroid. A fundamental and clinical text. Philadelphia: JB Lippincott 1991:759-70.
57. Iranmanesh A, Lizarralde G, Johnson ML, Veldhuis JD. Nature of altered growth hormone secretion in hyperthyroidism. J Clin Endocrinol Metab 1991;72: 108-15.
58. Iranmanesh A, Lizzarralde G, Johnson ML, Veldhuis JD. Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothyroidism assessed before and after partial thyroid hormone replacement. J Clin Endocrinol Metab 1990;70:155-61.
59. Walfish PG, Chan JY. Post-partum hyperthyroidism. Clin Endocrinol Metab 1985;14:417-17.
60. Winsa B. Graves' disease-Etiology, prognostic factors and treatment. Acta Univ Upsaliensis 1993:1-57.
61. Tao TW, Leu SL, Kriss JP. Biological activity of autoantibodies associated with Graves' dermopathy. J Clin Endocrinol Metab 1989;69:90-9.
62. Thjodleifsson B, Hedley AJ, Donald D, et al. Outcome of subtotal thyroidectomy for thyrotoxicosis in Iceland and Northeast Scotland. Clin Endocrinol 1977;7: 367-76.
63. Kasuga Y, Sugenoya A, Kobayashi S, et al. Clinical evaluation of the response to surgical treatment of Graves' disease. Surg Gynecol Obstet 1990;170: 327-30.
64. Tweedle D, Colling A, Schardt W, et al. Hypothyroidism following partial thyroidectomy for thyrotoxicosis and its relationship to thyroid remnant size. Br J Surg 1977;64:445-8.
65. Dydek GJ, Blue PW. Human breast milk excretion of iodine-131 following diagnostic and therapeutic administration to a lactating patient with Graves' disease. J Nucl Med 1988;29:407-10.
66. MacDougal IR. Which therapy for Graves' hyperthyroidism in children? Nucl Med Comm 1989;10:855-7.
67. Baverstock KF. Thyroid cancer in children in Belarus after Chernobyl. WHO Health Stat Q 1993;46:204-8.
68. Maxon HR, Thomas SR, Saenger EL, Buncher CR, Kereiakes JG. Ionizing irradiation and the induction of clinically significant disease in the human thyroid gland. Am J Med 1977;63:967-78.
69. Holm LE, Hall P, Wiklund K, et al. Cancer risk after iodine-131 therapy for hyperthyroidism. J Natl Cancer Inst 1991;83:1072-7.
70. Refetoff S, Harrison J, Karanfilski BT, Kaplan EL, DeGroot LJ, Berkerman C. Continuing occurrence of thyroid carcinoma after irradiation to the neck in infancy and childhood. N Engl J Med 1975;292:171-5.
71. Tezelman S, Grossman RF, Siperstein AE, Clark OH. Radioiodine associated thyroid cancers. World J Surg 1994;18:522-8.
72. Mandel SJ, Brent GA, Larsen PR. Review of antithyroid drug use during pregnancy and report of a case of aplasia cutis. Thyroid 1994;4:129-33.
73. Graham GD, Burman KD. Radioiodine treatment of Graves' disease, an assessment of it's potential risks. Ann Intern Med 1986;105:900-5.
74. Hales I, McElduff A, Crummer P, et al. Does Graves' disease or thyrotoxicosis affect the prognosis of thyroid cancer. J Clin Endocrinol Metab 1992;75:886-9.
75. Ross DS. The medical management of Graves' disease. Endocr Pract 1995;1:193-9.
76. Rudberg C, Johansson H, Åkerström G, Tuvemo T, Karlsson FA. Graves' disease in children and adolescents. Late results of surgical treatment. Eur J Endocrinol 1996;134:710-5.
77. Perzik SL. Total thyroidectomy in Graves' disease in children. J Pediatr Surg 1976;11:191-3.
78. Thompson NW, Dunn EL, Feritas JE, Sisson JC, Coran AG, Nishiayma RH. Surgical treatment of thyrotoxicosis in children and adolescents. J Pediatr Surg 1977; 12:1009-18.
79. Soreide JA, van Heerden JA, Lo CY, Grant CS, Zimmerman D, Ilstrup DM. Surgical treatment of Graves' disease in patients younger than 18 years. World J Surg 1996;20:794-800.
80. Sugino K, Mimura T, Ozaki O, et al. Management of recurrent hyperthyroidism in patients with Graves' disease treated by subtotal thyroidectomy. J Endocrinol Invest 1995;18:415-9.
81. Michie W, Pegg CAS, Bewsher PD. Prediction of hypothyroidism after partial thyroidectomy for thyrotoxicosis. Br Med J 1972;1:13-7.
82. Sugrue DD, Drury MI, McEvoy M, Heffernan SJ, O'Malley E. Long term follow-up of hyperthyroid patients treated by subtotal thyroidectomy. Br J Surg 1983;70:408-11.
83. Graham GD, Burman KD. Radioiodine treatment of Graves' disease. An assement of its potential risk. Ann Intern Med 1986;105:900-5.
84. Bodolay E, Suranyi P, Juhasz F, Stenszky V, Balazs C, Farid NR. Methimazole blocks Graves' IgG but not interferon-gamma HLA-DR expression by thyroid cells. Immunol Lett 1988;18:167-71.
85. Karlsson FA, Tötterman T. Immunomodulation by methimazole therapy in Graves' disease: Rapid changes in activation stage of circulating regulatory T cell subsets, B cells and NK cells. Clin Exp Immunol 1988;74:258-63.
86. Wilson R, McKillop JH, Pearson C, Burnett AK, Thomson JA. Differential immunosuppressive action of carbimazole and propylthiouracil. Clin Exp Immunol 1988;73:312-5.
87. Cooper DS, Goldminz D, Levin AA, Ladenson PW, Daniels GH, Molitch ME, Ridgway EC. Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. Ann Intern Med 1983;98:26-9.
88. Cooper DS. Antithyroid drugs. N Engl J Med 1984; 311:1353-62.
89. Hashizume K, Ichikawa K, Sakurai A, et al. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimualting hormone receptors and on the risk of recurrence of hyperthyroidism. N Eng J Med 1991;324:947-53.
90. Tamai H, Hayaki I, Kawai K, et al. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves disease patients. J Clin Endocrinol Metab 1995; 80:1481-1.
91. Hedley AJ, Young RE, Jones SJ, Alexander WD, Bewsher PD. Antithyroid drugs in the treatment of hyperthyroidism of Graves' disease: Long-term follow-up of 434 patients. Clin Endocrinol 1989;31:209-18.
92. Solomon BL, Evaul JE, Burman KD, Wartofsky L. Remission rates with antithyroid drug therapy: Continuing influence of iodine intake? Ann Intern Med 1987; 107:510-2.
93. DeBruin TWA, Bolk JH, Bussemaker JK, Stijnen T, Schreuder GMT, DeVries RRP, van der Heide. Graves' disease: Immunological and immunogenetic indicators of relapse. Br Med J 1988;296:1292-5.
94. Meurisse M, Hamoir E, D'Silva M, Joris J, Hennen G. Amiodarone-induced thyrotoxicosis: Is there a place for surgery? World J Surg 1993;17:622-7.
95. Emerson CH, Anderson AJ, Howard WJ, Utiger RD. Serum thyroxine and triiodothyronine concentrations during iodide treatment of hyperthyroidism. J Clin Endocrinol Metab 1975;40:33-6.
96. Peek CM, Sawers JSA, Irvine WJ, Beckett GJ, Ratcliffe WA, Toft AD. Combination of potassium iodide and propranolol in preparation of patients with Graves' disease for thyroid surgery. N Engl J Med 1980;302: 883-5.
97. Chang DCS, Wheeler MH, Woodcock JP, et al. The effect of preoperative Lugol's iodine on thyroid blood flow in patients with Graves' hyperthyroidism. Surgery 1987;102:1055-61.
98. Lee TC, Coffey RJ, Currier BM, Xiu-Ping MA, Canary JJ. Propranolol and thyroidectomy in the treatment of thyrotoxicosis. Ann Surg 1982;195:766-73.
99. Vickers P, Garg KM, Arya R, Godha U, Matur P, Jain S. The role of selective β1-blocker in the preoperative preparation of thyrotoxicosis: A comparative study with propranolol. Int Surg 1990;75:179-83.
100. Lennquist S, Jörtsjö E, Anderberg B, Smeds S. Betablockers compared with antithyroid drugs as preoperative treatment in hyperthyroidism: Drug tolerance, complications, and postoperative thyroid function. Surgery 1985;98:1141-7.
101. Marigold JH, Morgan AK, Earle DJ, Young AE, Croft DN. Lugol's iodine: Its effect on thyroid blood flow in patients with thyrotoxicosis. Br J Surg 1985;72:45-7.
102. Toft AD, Irvine WJ, McIntosh D, MacLeod DAD, Seth J, Cameron EHD, Lidgard GP. Propranolol in the treatment of thyrotoxicosis by subtotal thyroidectomy. J Clin Endocrinol Metab 1976;43:1312-6.
103. Coyle PJ, Mitchell JE. Thyroidectomy: Is Lugol's iodine necessary. Ann R Coll Surg 1982;64:334-5.
104. Mazzaferri EL, Reynolds JC, Young RL, Thomas CN, Parisi AF. Propranolol as primary therapy for thyrotoxicosis. Arch Intern Med 1976;136:50-6.
105. Steel NR, Taylor JJ, Young ET, Farndon JR, Holcombe M, Kendall-Taylor P. The effect of subtotal thyroidectomy with propranolol preparation on antibody activity in Graves' disease. Clin Endocrinol 1987;26:97-106.
106. Toft AD, Irvine WJ, Sinclair I, McIntosh D, Seth J, Cameron EH. Thyroid function after surgical treatment to thyrotoxicosis: A report of 100 cases treated with propranolol before operation. N Engl J Med 1978; 298:643-7.
107. Eriksson M, Ruberfeld S, Garber JA, Kohler P. Propranolol does not prevent thyroid storm. N Engl J Med 1977;296:263-4.
108. Grubeck-Loebenstein B, Derfler K, Kassal H, et al. Immunological features of nonimmunogenic hyperhyroidism. J Clin Endocrinol Metab 1985;60:150-5.
109. Nobori MN, Saiki S, Tanaka N, Harihara Y, Shindo S, Fujimoto Y. Blood supply of the parathyroid gland from the superior thyroid artery. Surgery 1994;115:417-23.
110. Lennquist S, Cahlin C, Smeds S. The superior laryngeal nerve in thyroid surgery. Surgery 1987;102: 999-1008.
111. Thompson NW, Olsen WR, Hoffman GL. The continuing development of the technique of thyroidectomy. Surgery 1973;73:913-21.
112. Saxe A. Parathyroid transplantation: A review. Surgery 1984;95:507-26.
113. Paloyan E, Lawrence AM, Brooks MH, Pickelman JR. Total thyroidectomy and autotransplantation for radiation-associated thyroid cancer. Surgery 1976;80:70-6.
114. Cusick EL, Krukowiski ZH, Matheson NA. Outcome of surgery for Graves' disease re-examined. Br J Surg 1987;74:780-3.
115. Noguchi S, Murakama N, Noguchi A. Surgical treatment for Graves' disease: Along term follow-up of 325 patients. Br J Surg 1981;68:105-8.
116. Lennquist S. The thyroid nodule: Diagnosis and surgical treatment. Surg Clin N Am 1987;67:213-32.
117. Perzik SL. Total thyroidectomy in the management of Graves' disease. Am J Surg 1976;131:284-7.
118. Catz B, Perzik SL. Total thyroidectomy in the management of thyrotoxic and euthyroid Graves' disease. Am J Surg 1969;118:434-9.
119. Werner SC, Feind CR, Aida M. Graves' disease and total thyroidectomy. Progression of severe eye changes and decrease in serum long acting thyroid stimulator after operation. N Engl J Med 1967;276:132-7.
120. Sugino K, Mimura T, Ozaki O, et al. Preoperative change of thyroid stimulating hormone receptor antibody level: Possible marker for predicting recurrent hyperthyroidism in patients with Graves' disease after subtotal thyroidectomy. World J Surg 1996;20:801-7.
121. Lennquist S, Persliden J, Smeds S. Intraoperative scintigraphy in surgical treatment of thyroid carcinoma: Evaluation of a new technique. World J Surg 1986;10:711-7.
122. Busnardo B, Girelli ME, Rubello D, Eccher C, Betterle C. Long term thyroid function after subtotal thyroidectomy for Graves' disease. J Endocrinol Invest 1988; 11:371-4.
123. Okamoto T, Fujimoto Y, Obara T, Ito Y, Aiba M. Retrospective analysis of prognostic factors affecting the thyroid functional status after subtotal thyroidectomy for Graves' disease. World J Surg 1992;16:690-6.
124. Sugino K, Mimura T, Toshima K, et al. Follow-up evaluation of patients with Graves' disease treated by subtotal thyroidectomy and risk factor analysis of postoperative thyroid dysfunction. J Endocrinol Invest 1993; 16:195-9.
125. Reeve TS, Delbridge L, Cohen A, Crummer P. Total thyroidectomy: The preferred option for multinodular goiter. Ann Surg 1987;206:782-6.
126. Sugino K, Mimura T, Ozaki O, et al. Early recurrence of hyperthyroidism in patients with Graves' disease treated by subtotal thyroidectomy. World J Surg 1995; 19:648-52.
127. Jörtsjö E, Lennquist S, Lundström B, Norrby K, Smeds S. The influence of remnant size, antithyroid antibodies, thyroid morphology, and lymphocytic infiltration on thyroid function after subtotal resection for hyperthyroidism. World J Surg 1987;11:365-71.
128. Gillquist J, Lundström B, Larsson R, Sjödahl R, Bröte L, Anderberg B. Peroperative estimation of the size of the thyroid remnant. Acta Chir Scand 1979;145: 459-61.
129. Hosojima H, Miyauchi E, Okada H, Azukizawa S, Yamamoto I, Morimoto S. Changes in TSH-receptor antibody (TR-AB) and thyroid stimulating antibody (TS-AB) after thyroidectomy in thyrotoxic patients. Filia Endocrinol 1990;66:727-36.
130. 3 suppression tests and antithyroid antibodies in euthyroid patients. Acta Endocrinol 1983;103:28-33.
131. Harada T, Shimaoka K, Arita S, Nakanishi Y. Follow-up evaluation of thyroid function after thyroidectomy for thyrotoxicosis. World J Surg 1984;8:436-44.
132. Izumi M, Larsen PR. Correlation of sequential changes in serum thyroglobulin, triiodothyronine and thyroxine in patients with Graves' disease and subacute thyroiditis. Metabolism 1978;27:449-60.
133. Reid DJ. Hyperthyroidism and hypothyroidism complicating the treatment of thyrotoxicosis. Br J Surg 1987;74:1060-2.
134. Ilicki A, Gamstedt A, Karlsson FA. Hyperthyroid Graves' disease without detectable thyrotropin receptor antibodies. J Clin Endocrinol Metab 1992;74;1090-4.
135. Evered D, Young ET, Tunbridge WMG, et al. Thyroid function after subtotal thyroidectomy for hyperthyroidism. Br Med J 1975;1:25-7.
136. Frilling A, Goretzki P, Grussendorf M, Erbsloh M, Röher HD. The influence of surgery on endocrine ophthalmopathy. World J Surg 1990;14:442-6.
137. Levitt MD, Antony JE, Agnello R, McCormick CC. The effect of subtotal thyroidectomy on Graves' ophthalmopathy. World J Surg 1988;12:593-7.
138. Hamilton RD, Mayberry VE, McConahey WM, Hanson KC. Ophthalmopathy of Graves' disease: A comparison between patients treated surgically and patients treated with radioiodine. Mayo Clin Proc 1967; 42:812-8.
139. Barbosa J, Wong E, Doe RP. Ophthalmopathy of Graves' disease: Outcome after treatment with radioactive iodine, surgery or antithyroid drugs. Arch Intern Med 1972;130:111-3.
140. Catz B, Perzik SL. Subtotal vs. total surgical ablation of the thyroid. Malignant exophthalmos and its relation to remnant thyroid. In: Cassano C, Andreoli M, eds. Current topics in thyroid research. New York: Academic Press, 1965:1183-8.
141. Farnell MB, van Heerden JA, McConahey WM, Carpenter HA, Wolf LH. Hypothyroidism after thyroidectomy for Graves' disease. Am J Surg 1981;142:535-8.
142. Ozoux JP, de Calan L, Portier G, et al. Surgical treatment of Graves' disease. Am J Surg 1988;156:177-81.
143. Menegaux F, Ruprecht T, Chigot JP. The surgical treatment of Graves' disease. Surg Gynecol Obstet 1993; 176:277-82.
144. Maier WP, Derrick BM, Marks AD, Channick BJ, Au FC, Caswell HT. Long-term follow-up of patients with Graves' disease treated by subtotal thyroidectomy. Am J Surg 1984;147:266-8.
145. Bradley EL, Liechty RD. Modified subtotal thyroidectomy for Graves' disease. A two-institution study. Surgery 1983;94:955-8.